Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen

Journal of Nuclear Medicine

Volumn 48, Issue 1 SUPPL., 2007, Pages

  Kuehl, Hilmar ^a   Veit, Patrick ^a   Rosenbaum, Sandra J ^a   Bockisch, Andreas ^a   Antoch, Gerald ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Abdomen; Chest; Contrast material; Imaging protocols; PET CT

Indexed keywords

CISPLATIN; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; IMATINIB; MITOMYCIN;

ABDOMINAL CANCER; BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; COLON CANCER; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRYOTHERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GLUCOSE METABOLISM; HUMAN; LASER THERMOTHERAPY; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG CARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIOFREQUENCY ABLATION; RENAL PROTECTION; REVIEW; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THORAX CANCER; TREATMENT PLANNING; TREATMENT RESPONSE; WHOLE BODY SCINTISCANNING; ABDOMINAL RADIOGRAPHY; ABDOMINAL TUMOR; CLINICAL PRACTICE; IMAGE QUALITY; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; THORAX TUMOR; WHOLE BODY IMAGING;

ABDOMINAL NEOPLASMS; CONTRAST MEDIA; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES; RADIOGRAPHIC IMAGE ENHANCEMENT; RADIOGRAPHY, ABDOMINAL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THORACIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 33947584715     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Feuerbach S, Lorenz W, Klose KJ, et al. Contrast medium administration in spiral CT: the results of a consensus conference. RöFo. 1996;164:158-165.
2. Yamashita Y, Komohara Y, Takahashi M, et al. Abdominal helical CT: evaluation of optimal doses of intravenous contrast material - a prospective randomised study. Radiology. 2000;216:718-723.
3. 18F-FDG PET/CT. J Nucl Med. 2004;45(suppl 1):56S-65S.
4. Nakamoto Y, Chin BB, Kraitchman DL, Lawler LP, Marshall LT, Wahl RL. Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. Radiology. 2003;227:817-824.
5. Antoch G, Freudenberg LS, Egelhof T, et al. Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med. 2002;43:1339-1342.
6. Yau YY, Chan WS, Tam YM, et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error? J Nucl Med. 2005;46:283-291.
7. Berthelsen AK, Holm S, Loft A, Klausen TL, Andersen F, Hojgaard L. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging. 2005;32:1167-1175.
8. Herman S. CT contrast enhancement principles and the use of high-concentration contrast material. J Comput Assist Tomogr. 2004;28(suppl 1):S7-S11.
9. Awai K, Imuta M, Utsunomiya D, et al. Contrast enhancement for whole-body screening using multidetector row helical CT: comparison between uniphasic and biphasic injection protocols. Radiat Med. 2004;22:303-309.
10. 18F-FDG PET/CT examinations. J Nucl Med. 2005;46:608-613.
11. Von Schulthess GK. Maximising the benefit of integrated PET/CT: the road ahead. Eur J Nucl Med Mol Imaging. 2004;31:1462-1463.
12. 68Ge attenuation correction in a combined PET/CT system: evaluation of the effect of lowering the CT tube current. Eur J Nucl Med Mol Imaging. 2002;29:346-350.
13. Antoch G, Kuehl H, Kanja J, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology. 2004;230:879-885.
14. 18F-FDG PET/CT. J Nucl Med. 2005;46:429-435.
15. Beyer T, Tellmann L, Nickel I, Pietrzyk U. On the use of positioning aids to reduce misregistration in the head and neck in whole-body PET/CT studies. J Nucl Med. 2005;46:596-602.
16. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system - initial results. Radiology. 2002;225:575-581.
17. Suzuki K, Yamamoto M, Hasegawa Y, et al. Magnetic resonance imaging and computed tomography in the diagnoses of brain metastases of lung cancer. Lung Cancer. 2004;46:357-360.
18. Belhocine T, Weiner SM, Brink I, et al. A plea for the elective inclusion of the brain in routine whole-body FDG PET. Eur J Nucl Med Mol Imaging. 2005;32:251-256.
19. Czernin J, Allen-Auerbach MA. Clinical PET/CT imaging: promises and misconceptions. Nuklearmedizin. 2005;44(suppl):S18-S24.
20. Bepler G, Goodridge Carney D, Djulbegovic B, Clark RA, Tockman M. A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest. Cancer Control. 2003;10:306-314.
21. Brenner DJ. Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. Radiology. 2004;231:440-445.
22. Yamada T, Ono S, Tsuboi M, et al. Low-dose CT of the thorax in cancer follow-up. Eur J Radiol. 2004;51:169-174.
23. Zhu X, Yu J, Huang Z. Low-dose chest CT: optimizing radiation protection for patients. AJR. 2004;183:809-816.
24. Goerres GW, Kamel E, Heidelberg TN, Schwitter MR, Burger C, von Schulthess GK. PET-CT image co-registration in the thorax: influence of respiration. Eur J Nucl Med Mol Imaging. 2002;29:351-360.
25. Beyer T, Antoch G, Muller S, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med. 2004;45(suppl 1):25S-35S.
26. Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging. 2003;30:588-596.
27. Beyer T, Rosenbaum S, Veit P, et al. Respiration artifacts in whole-body (18)FFDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1 to 16 detector rows. Eur J Nucl Med Mol Imaging. 2005;32:1429-1439.
28. Alberts WM. Lung cancer guidelines: introduction. Chest. 2003;123(1 suppl):1S-2S.
29. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
30. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology. 2003;229:526-533.
31. 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:8362-8370.
32. Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg. 2004;78:1903-1909.
33. Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest. 2003;123(suppl): 147S-156S.
34. Halpern BS, Schiepers C, Weber WA, et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest. 2005;128:2289-2297.
35. Nehmeh SA, Erdi YE, Pan T, et al. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys. 2004;31:3179-3186.
36. 18F- fluoro-2-deoxy-Dglucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res. 2006;12:97-106.
37. 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med. 2004;45:1640-1646.
38. Pestalozzi BC, Luporsi-Gely E, Jost LM, Bergh J, ESMO Guidelines Task Force. ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol. 2005;16(suppl 1):i7-i9.
39. Mollick JA, Carlson RW. Rational surveillance programs for early stage breast cancer patients after primary treatment. Breast Dis. 2004;21:47-54.
40. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging. October 29, 2005 [Epub ahead of print].
41. Scheidhauer K, Walter C, Seemann MD. FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions. Eur J Nucl Med Mol Imaging. 2004;31(suppl 1):S70-S79.
42. Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positronemission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003;38:250-256.
43. 18F-FDG PET. J Nucl Med. 2005;46:1144-1150.
44. Lind P, Igerc I, Beyer T, Reinprecht P, Hausegger K. Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging. 2004;31(suppl 1):S125-S134.
45. Fueger BJ, Weber WA, Quon A, et al. Performance of 2-deoxy-2-[F-18] fluoro-Dglucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol. 2005;7:369-376.
46. Nakai T, Okuyama C, Kubota T, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253-1258.
47. 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res. 2000;20:2189-2192.
48. 18F-fluoride PET/CT. J Nucl Med. 2004;45:272-278.
49. Ghanem N, Uhl M, Brink I, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol. 2005;55:41-55.
50. American Cancer Society. Cancer Facts and Figures 2005. Atlanta, GA: American Cancer Society; 2005.
51. Hoyert DL, Kung HC, Smith BL. Deaths: preliminary data for 2003. Natl Vital Stat Rep. 2005;53:1-48.
52. National Center of Health Statistics. Health, US, 2004. With Chartbook on Trends in the Health of Americans. Hyattsville, MD: National Center of Health Statistics; 2004.
53. Alberts S, Poston GJ. OncoSurge: a strategy for long-term survival in metastatic colorectal cancer. Colorectal Dis. 2003;5(suppl S3):20-28.
54. Poston GJ. Radiofrequency ablation of colorectal liver metastases: where are we really going? J Clin Oncol. 2005;23:1342-1344.
55. Setty BN, Blake MA, Sahani DV, Holalkere NS, Fischman AJ. Role of contrastenhanced CT (CECT) in hybrid PET-CT for liver metastases in patients with colorectal cancer. In: Scientific Program of RSNA 2005, 91st Scientific Assembly and Annual Meeting; November 27-December 2, 2005; Chicago, IL; p. 452.
56. Veit P, Kuhle C, Beyer T, et al. Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer. Gut. 2006;55:68-73.
57. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002;38(suppl 5): S60-S65.
58. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012-2020.
59. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45:357-365.
60. Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology. 2005;235:892-898.
61. Head HW, Dodd GD III. Thermal ablation for hepatocellular carcinoma. Gastroenterology. 2004;127(5 suppl 1):S167-S178.
62. Ruers TJ, Langenhoff BS, Neeleman N, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol. 2002;20:388-395.
63. Arulampalam TH, Francis DL, Visvikis D, Taylor I, Ell PJ. FDG-PET for the pre-operative evaluation of colorectal liver metastases. Eur J Surg Oncol. 2004;30:286-291.
64. Teefey SA, Hildeboldt CC, Dehdashti F, et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology. 2003;226:533-542.
65. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32:792-797.
66. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol. 2004;39:961-968.
67. Wallace JR, Christians KK, Quiroz FA, Foley WD, Pitt HA, Quebbeman EJ. Ablation of liver metastasis: is preoperative imaging sufficiently accurate? J Gastrointest Surg. 2001;5:98-107.
68. Kuehl H, Antoch G, Rosenbaum S, Veit P, Barkhausen J, Bockisch A. Preinterventional whole-body PET/CT in patients with malignant liver tumors: influence on patient management to RF ablation therapy [abstract]. Eur Radiol. 2005;15(suppl 1):294.
69. Antoch G, Vogt FM, Veit P, et al. Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. J Nucl Med. 2005;46:520-525.
70. Kuehl H, Veit P, Rosenbaum S, Antoch G, Bockisch A. Follow-up of malignant liver tumors treated with RF ablation: comparison of PET/CT and MR imaging. In: Scientific Program of RSNA 2005, 91st Scientific Assembly and Annual Meeting; November 27-December 2, 2005; Chicago, IL; p. 74.